Skip to main content
. 2013 Sep 5;43(10):945–953. doi: 10.1093/jjco/hyt131

Figure 4.

Figure 4.

Mode of action of TAS-114C. 5-FU is rapidly degraded by DPD. Therefore, 5-FU-based drugs without a DPD inhibitor (i.e. capecitabine) need massive dosing for cancer treatment although this may cause a higher incidence of HFS. Combination with TAS-114 could reduce the dose of capecitabine by DPD inhibition while maintaining adequate tumor 5-FU levels. On the other hand, the antitumor activity of capecitabine may increase by dUTPase inhibition.